Autism Disorder and Treatment Market Research Report - Forecast to 2023

Autism Disorder and Treatment Market Research Report - Forecast to 2023

ID: MRFR/HC/1074-CRR | April, 2018 | Region: Global | 108 pages | Cooked Research Reports

Autism Disorder & Treatment Market Information: By Type (Asperger Syndrome, Pervasive Developmental Disorder, Others), by Treatment Type (Aba, Hyperbaric Oxygen Therapy, and Others), by Drug (SSRIs, Anti-Convulsant, Others) – Global Forecast Till 2023


Market Scenario


Autism Spectrum Disorder (ASD) is a range of conditions caused by challenges with social skills, speech and nonverbal communication, repetitive behaviors, along with unique strengths and differences. This condition is caused by different combinations of genetic and environmental influences. Autism tends to show its most-obvious signs between two and three years of age. In various cases, it can be diagnosed within 18 months of the child’s birth.


The global autism disorder and treatment market has been identified as one of the rapidly growing industries, owing to rising prevalence of autism and Pervasive Developmental Disorder (PDD) and rising awareness about autism among the patient population. Autism disorder and treatment is observed as one of the significantly growing markets in the healthcare sector because of initiatives taken by the government of various nations and expected approvals of various off-label treatment therapies by the Food and Drug Association (FDA).


With the upsurge in the market, there are some hindrances faced by the market such as a weak pipeline of drugs for autism disorder and unknown etiology and pathophysiology of ASD.


Global Autism Disorder & Treatment Market is expected to grow at a CAGR of 4.37% during the forecast period 2017–2023.


Intended Audience



  • Drugs Manufacturers for Autism disorder

  • Drugs Suppliers for Autism disorder

  • Training & Service providers for autism disorder

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Research Methodology


 Autism Disorder & Treatment Market


Source: Sources: World Health Organization (WHO), Centers for Disease Control's (CDC), Autism and Developmental Disabilities Monitoring (ADDM) society, U.S. Food and Drug Administration (FDA), Human Resources & Service Administration (HRSA), Autism Speaks, expert interview, market research future analysis, annual report, white paper, company presentation


Segmentation                                                                                                                                      


The Global autism disorder & treatment market is segmented by type, treatment type, and drugs.


By type, it is segmented into Asperger Syndrome, Pervasive Developmental Disorder, and others.


By treatment type, it is segmented into ABA (applied behavioral analysis), hyperbaric oxygen therapy, chelation therapy, oxytocin therapy, and others.


By drug, it is segmented into SSRIs, anti-convulsant, stimulants, anti-psychotic. Anti-psychotics are further segmented into Abilify (aripiprazole) and Risperidone.


Figure: Global Autism Disorder & Treatment Market, by Treatment Type, 2016 (%)


 Autism Disorder & Treatment Methedology


Source Autism and Developmental Disabilities Monitoring (ADDM) society, U.S. Food and Drug Administration (FDA), Human Resources & Service Administration (HRSA), Autism Speaks, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Key Findings



  • The global autism disorder & treatment market was USD 5,143.6 million in 2016

  • The pervasive developmental disorder is the largest segment, by type which is projected to grow at a CAGR of 4.73% during the forecast period from 2017–2023.

  • ABA is the largest segment, by treatment type in global and expected to grow at a rate of CAGR 4.82% during the forecast period

  • The anti-psychotic accounted for the largest market share in global autism disorder & treatment market by drugs and is expected grow with the CAGR of 3.95% for the forecast period.


Regional Analysis


The global autism disorder & treatment market is segmented into four regions namely the Americas, Europe, Asia Pacific, and the Middle East & Africa, with Americas holding the largest market share followed by Europe. In Americas, North America accounted for the largest market owing to the increasing screening of autism cases in this region. Additionally, the approval and expected launch of the atypical anti-psychotic such as Latuda and Namenda is expected to generate increased sales in the U.S. post-approval. Asia Pacific is expected to be the fastest growing market while the Middle East & Africa exhibit steady and growth during the forecast period. As per the epidemiological studies conducted over the past 50 years have suggested that the prevalence of ASD is increasing globally. Some of the factors responsible for the increasing prevalence are improved awareness, expansion of diagnostic criteria, better diagnostic tools and improved reporting.


Key Players


Some of the key players in this market are Pfizer Inc., Eli Lilly and Company, Allergan, Merck & CO Inc., Teva Pharmaceutical Industries Ltd., Consern Pharma Private Limited, Novartis AG, Johnson & Johnson Services, Inc. Bristol-Myers Squibb and Otsuka Holdings Co., Ltd., Coronis Partners Ltd., Curemark LLC, Heptares Therapeutics Limited, Intra-Cellular Therapies Inc., Saniona AB, and few others.

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

TABLE OF CONTENTS

2.1 Scope of Study 17

2.2 Research Objective 17

2.3 Assumptions & Limitations 17

2.3.1 Assumptions 17

2.3.2 Limitations 17

3.1 Primary Research Methodology 19

3.2 Secondary Research Methodology 20

3.3 Market Share Analysis 21

3.4 Trade Analysis 21

3.5 Market Pricing Approach 21

4.1 Introduction 23

4.2 Drivers 24

4.2.1 Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD) 24

4.2.2 Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth 25

4.2.3 Rising government or privately held societies taking initiatives to create the awareness about the disease 26

4.3 Restraints 27

4.3.1 Weak Product Pipeline of First Drugs for Autism 27

4.3.2 Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options 28

4.4 Opportunities 29

4.4.1 Rising Investments by Venture Non-Pharmacology Activities 29

4.5 Mega Trends 30

4.6 Macroeconomic Indicators

5.1 Porter’s Five Forces Model 32

5.1.1 Bargaining Power of Suppliers 33

5.1.2 Bargaining Power of Buyers 33

5.1.3 Threat of New Entrants 33

5.1.4 Threat of Substitutes 33

5.1.5 Intensity of Rivalry 33

5.2 Value Chain Analysis 34

5.2.1 R&D 34

5.2.2 Manufacturing 34

5.2.3 Distribution & Sales 34

5.2.4 Post-Sales Monitoring 35

5.3 Pricing Analysis 36

5.4 Investment Opportunity Analysis 36

5.5 Demand & Supply: Gap Analysis 36

6.1 Introduction 39

6.2 Asperger Syndrome 40

6.3 Pervasive Developmental Disorders (PDD) 40

7.1 Introduction 42

7.2 Expert Opinion: Oxytocin 42

7.3 ABA (applied behavioral analysis) 43

7.4 Hyperbaric oxygen therapy 44

7.5 Chelation therapy 44

7.6 Oxytocin therapy 44

8.1 Introduction 46

8.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 47

8.3 Anti-convulsants 48

8.4 Stimulants 48

8.5 Anti-psychotic 48

9.1 Introduction 50

9.2 Americas 51

9.3 North America 54

9.3.1 U.S. 54

9.4 Canada 55

9.4.1 South America 56

9.5 Europe 57

9.5.1 Germany 60

9.5.2 France 61

9.5.3 U.K. 62

9.5.4 Italy 63

9.5.5 Spain 64

9.5.6 Rest of Western Europe 65

9.5.7 Eastern Europe 66

9.6 Asia Pacific 67

9.6.1 Japan 69

9.6.2 China 70

9.6.3 India 71

9.6.4 Australia 72

9.6.5 Republic of Korea 73

9.6.6 Rest of Asia Pacific 74

9.7 Middle East & Africa 76

9.7.1 U.A.E. 78

9.7.2 Saudi Arabia 79

9.7.3 Oman 80

9.7.4 Kuwait 81

9.7.5 Qatar 82

9.7.6 Rest of the Middle East & Africa 83

10.1 Company Market Share Analysis 86

10.1.1 Introduction 86

10.2 Competitive Landscape 87

10.2.1 Introduction 87

10.3 Recent Developments, 2013–2018 88

11.1 Pfizer Inc. 91

11.1.1 Company Overview 91

11.1.2 Financials 91

11.1.3 Products 91

11.1.4 Strategy 91

11.1.5 Key Developments 91

11.2 Allergan, Plc 92

11.2.1 Company Overview 92

11.2.2 Financials 92

11.2.3 Products 92

11.2.4 Strategy 92

11.2.5 Key Developments 92

11.3 Eli Lilly and Company 93

11.3.1 Company Overview 93

11.3.2 Financials 93

11.3.3 Products 93

11.3.4 Strategy 93

11.3.5 Key Developments 93

11.4 Bristol-Myers Squibb Company 94

11.4.1 Company Overview 94

11.4.2 Financials 94

11.4.3 Products 94

11.4.4 Strategy 94

11.4.5 Key Developments 94

11.5 Sun Pharmaceutical Industries Ltd. 95

11.5.1 Company Overview 95

11.5.2 Financials 95

11.5.3 Products 95

11.5.4 Strategy 95

11.5.5 Key Developments 95

11.6 Johnson & Johnson Services, Inc. 96

11.6.1 Company Overview 96

11.6.2 Financials 96

11.6.3 Products 96

11.6.4 Strategy 96

11.6.5 Key Developments 96

11.7 Teva Pharmaceutical Industries Ltd. 97

11.7.1 Company Overview 97

11.7.2 Financials 97

11.7.3 Products 97

11.7.4 Strategy 97

11.7.5 Key Developments 97


11.8 Merck & Co. Inc 98

11.8.1 Company Overview 98

11.8.2 Financials 98

11.8.3 Products 98

11.8.4 Strategy 98

11.8.5 Key Developments 98

11.9 Novartis AG 99

11.9.1 Company Overview 99

11.9.2 Financials 99

11.9.3 Products 99

11.9.4 Strategy 99

11.9.5 Key Developments 99

11.10 Otsuka Holdings Co. Ltd 100

11.10.1 Company Overview 100

11.10.2 Financials 100

11.10.3 Products 100

11.10.4 Strategy 100

11.10.5 Key Developments 100

11.11 Consern Pharma Private Limited 101

12.1 Key Findings 103

12.1.1 CEO’s Viewpoint 103

12.1.2 Key Companies to Watch 103

12.1.3 Prediction of Dietary Supplements in an Age of Personalized Nutrition Industry 103

13.1 Discussion Blue Print 105

13.2 Expert Opinion: Oxytocin 107

13.3 References 107